This funding is earmarked for general corporate purposes, including the further development of its Optejet device and commercialization efforts for products like Mydcombi and clobetasol propionate.

This funding is earmarked for general corporate purposes, including the further development of its Optejet device and commercialization efforts for products like Mydcombi and clobetasol propionate.

and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and ...